Autopsy report · NCT00934518

Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

“Inadequate patient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Milton S. Hershey Medical Center

Sponsor type

University, hospital or other

Conditions

Squamous Cell Cancer of the Head and Neck

Interventions

Radiation; Cetuximab

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (93% match in meaning)
• Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
  “Poor patient accrual” (93% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (86% match in meaning)
• SOX as Salvage Treatment in Nasopharyngeal Carcinoma
  “poor accrual of eligible patients” (84% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.